Deutetrabenazine (Austedo)

What it treats

Deutetrabenazine is approved by the U.S. Food and Drug Administration for two things: tardive dyskinesia in adults, and chorea associated with Huntington disease. Both are movement disorders driven by too much dopamine signaling in certain motor circuits.

Tardive dyskinesia (TD) most often shows up after longer exposure to antipsychotics or, less commonly, other dopamine-blocking drugs like metoclopramide. The movements are typically in the face, mouth, and tongue, sometimes the trunk or limbs, and they can be socially disabling. Chorea in Huntington disease is a genetically driven, progressive movement disorder that VMAT2 inhibitors can quiet.

How it works

Deutetrabenazine blocks a small protein called VMAT2 (vesicular monoamine transporter 2) inside nerve cells. VMAT2 is what loads dopamine (and to a lesser extent norepinephrine and serotonin) into the little packets that get released at the nerve terminal. Block the loading step and less dopamine gets released.

For tardive dyskinesia and Huntington chorea, less dopamine release in motor pathways means quieter movements. It's a presynaptic strategy, which is different from how antipsychotics work (those block dopamine receptors on the receiving side). One useful consequence: adjusting deutetrabenazine doesn't usually make TD movements worse the way tweaking an antipsychotic sometimes does.

Receptor mechanism (detail)

Deutetrabenazine inhibits the vesicular monoamine transporter type 2 (VMAT2) on the storage vesicles inside monoamine nerve terminals. This depletes presynaptic dopamine (and to a smaller degree serotonin and norepinephrine) available for release. The molecule is the deuterated form of tetrabenazine. Swapping hydrogen for deuterium at key positions slows metabolism by CYP2D6, which lengthens the half-life of the active metabolites and smooths out plasma levels.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Starting dose is 6 mg twice daily, taken with food. The dose is titrated up weekly by 6 mg per day based on response and tolerability. A common therapeutic range for tardive dyskinesia is 24 to 48 mg per day divided twice daily. Huntington chorea sometimes reaches slightly higher doses. The extended-release version (Austedo XR) lets the total daily dose go into one morning dose once the patient is stable.

CYP2D6 poor metabolizers and patients on strong CYP2D6 inhibitors need a lower ceiling on the dose, because they clear the active metabolites more slowly. Genotyping isn't required at low doses, but it becomes relevant as the daily dose climbs.

Safety monitoring

• QTc on ECG at baseline and after dose changes, especially at higher doses or in combination with other QT-prolonging drugs.
• Depression and suicidal thoughts, particularly in Huntington disease. This is a boxed warning in that population.
• Sedation, akathisia, and parkinsonism (slowed movement, stiffness). These are dopamine-depletion side effects that can look like TD returning.
• Blood pressure and pulse, especially early in titration or with other blood pressure medications.
• Liver function in patients with hepatic impairment; use caution and dose adjust.

What to expect

Some reduction in movements often shows up in the first few weeks of dose titration, but the fuller effect settles in once you're at a stable therapeutic dose, usually four to eight weeks in. TD tends to fluctuate day to day, so response is judged on the trend, not any single day.

Early side effects, when they appear, are usually mild sedation or a slightly slowed feeling. Splitting the dose and taking it with food helps. Akathisia (a restless, need-to-move feeling) can show up during titration and is worth reporting.

Common side effects

Most people tolerate it reasonably well, but the ones that show up most often include:

• Somnolence or fatigue.
• Diarrhea.
• Dry mouth.
• Insomnia.
• Nausea.
• Akathisia or restlessness.
• Mild parkinsonism (slowness, stiffness).

Many of these ease as the dose settles. If a side effect is dose-related, a small pull-back often solves it without losing the movement benefit.

Serious side effects and warnings

Serious problems are uncommon, but a few need to be understood before starting.

Boxed warning. In patients with Huntington disease, deutetrabenazine can increase the risk of depression and suicidal thoughts or actions. Anyone with Huntington disease taking it should be watched closely for mood change, and it's generally avoided in people with active, untreated depression or recent suicidal thinking. The boxed warning specifically calls out the Huntington population, but mood should be checked in any patient on the drug.

• QT prolongation. Higher doses raise QTc. Combining with other QT-prolonging drugs (some antipsychotics, methadone, certain antibiotics) needs care.
• Neuroleptic malignant syndrome. Rare but reported. Fever, rigidity, altered mental status, autonomic instability. Emergency.
• Parkinsonism and akathisia. Because the mechanism is dopamine depletion, deutetrabenazine can produce the very side effects antipsychotics cause. Reducing the dose usually helps.
• Sedation and impaired driving early in titration.

Sexual and relational effects

Sexual side effects aren't a major feature. Some people report reduced desire, likely tied to sedation or dopamine depletion. If something shifts after starting it, that's worth bringing up with the prescriber.

Weight, appetite, and sleep

Weight and appetite aren't strongly affected by deutetrabenazine. Sleep can go either way. Some people feel sedated (especially early), and some develop insomnia. Splitting the dose and shifting timing usually helps.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Deutetrabenazine comes as immediate-release tablets (6, 9, and 12 mg) and an extended-release tablet (Austedo XR) that consolidates the total daily dose into one morning tablet. Immediate-release tablets are taken with food to smooth absorption. The dose is titrated weekly, not all at once, and there's no benefit to jumping levels.

Missed doses and interactions

If you miss a dose, take it as soon as you remember unless the next scheduled dose is close. Don't double up.

CYP2D6 is the main pathway that clears the active metabolites. Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) raise blood levels and require a lower maximum dose. MAO inhibitors shouldn't be combined with deutetrabenazine. Combining with reserpine is a hard no. QT-prolonging drugs need caution. Alcohol adds to sedation and isn't recommended during titration. Give every prescriber and pharmacist a full list of your medications and supplements.

Stopping and tapering

Deutetrabenazine can be stopped without a formal taper in most cases, but tardive dyskinesia or chorea will typically return over days to weeks once the drug is out. If it's being stopped because of a side effect, the return of movements is expected and the plan should be worked out with the prescriber ahead of time. Long treatment breaks generally aren't recommended without a clear reason.

Pregnancy and breastfeeding

Data on deutetrabenazine in pregnancy is limited. It's used cautiously, and only when the movement disorder is functionally significant. Whether it enters breast milk in meaningful amounts isn't well characterized. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so specific risks and benefits can be weighed.

Cost and generic availability

Deutetrabenazine is brand-only (Austedo and Austedo XR) and is expensive. There's no generic as of this review date. Manufacturer assistance and specialty pharmacy programs are often part of getting it filled. Insurance approval usually requires documentation of the diagnosis and, for TD, some record of prior antipsychotic exposure.

Common questions

Is this the same as tetrabenazine? Chemically it's very close. Deutetrabenazine is the deuterated form, which changes how the body breaks it down. The practical result is twice-daily dosing (or once-daily with the ER), a smoother plasma curve, and generally fewer side effects than tetrabenazine.

Do I have to stop my antipsychotic? Usually not. Many people take deutetrabenazine alongside a continuing antipsychotic for schizophrenia or bipolar disorder. The decision to keep, switch, or lower the antipsychotic is a separate conversation, and switching to a lower TD-risk antipsychotic is often part of the plan.

Will my TD movements come back if I stop? Often yes, over days to weeks. VMAT2 inhibitors treat the symptoms; they don't cure TD.

Why the QTc check? Higher doses can lengthen the QT interval on ECG. Most people don't run into trouble, but the baseline and follow-up ECGs are how the risk gets tracked, especially if you're on other medications that also affect QT.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• Do any of my current medications interact with it or my heart's QT?
• Should I have my CYP2D6 status checked before we go higher on the dose?
• What signs of depression or mood change should trigger a call?
• If it doesn't work well enough, what's the next step?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Deutetrabenazine (Austedo, Austedo XR) prescribing information.
• DailyMed, U.S. National Library of Medicine. Deutetrabenazine label.
• MedlinePlus, U.S. National Library of Medicine. Deutetrabenazine.
• National Institute of Mental Health. Mental health medications.
• American Academy of Neurology. Tardive syndromes treatment guideline.
• Huntington Study Group. Recommendations on the use of VMAT2 inhibitors for chorea in Huntington disease.